Skip to content


Blincyto (blinatumomab) is an antibody pharmaceutical. Blinatumomab was first approved as Blincyto on 2014-12-03. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. It is known to target B-lymphocyte antigen CD19 and T-cell surface glycoprotein CD3 epsilon chain.
Trade Name Blincyto
Common Name Blinatumomab
Indication lymphoid leukemia, precursor cell lymphoblastic leukemia-lymphoma
Drug Class Monoclonal antibodies
Get full access now